[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oral-mucositis-due-to-chemotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oral-mucositis-due-to-chemotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100615070","phase-4-using-a-steroid-mouthwash-to-prevent-mouth-sores-during-chemotherapy-100615070",false,"NCT07287826","Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy","Study for Dexamethasone Mouthwash in Lowering Episodes of Oral Mucositis Among Patients With Cancer: The SMILE Study","SMILE","Inclusion criteria:\n\n* ≥18 years old\n* Confirmed cancer diagnosis\n* Scheduled to receive or receiving chemotherapy known to be associated with oral mucositis (e.g., anthracyclines and taxanes)\n* Ability to provide informed consent\n* Ability to comply with study procedures\n\nExclusion criteria:\n\n* Current tobacco usage or usage within the past 6 weeks.\n* HIV\u002FAIDS\n* Gastrointestinal disorder (such as Crohn's disease, ulcerative colitis, or celiac disease)\n* History of cold sores (herpes simplex virus)\n* Herpes zoster (oral shingles) within the past 6 weeks\n* Active oral infections at the time of enrollment (e.g., candidiasis)\n* Known sensitivity or allergy to dexamethasone\n* Inability to self-administer or tolerate mouthwash protocol\n* Concurrent enrollment in conflicting clinical trials\n* Existing oral ulcers or oral mucositis at enrollment\n* Pregnant\n* Uncontrolled diabetes mellitus as defined by HbA1c unknown or \\>8% in the past 3 months despite adequate therapy","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn if a steroid mouthwash (dexamethasone) can prevent mouth sores caused by chemotherapy in adults with cancer. The main questions it aims to answer are:\n\nDoes using dexamethasone mouthwash before and during chemotherapy lower the chance of getting moderate to severe mouth sores?\n\nCan this approach reduce pain and improve comfort during chemotherapy?\n\nResearchers will compare patients using the mouthwash to a historical group of patients who received similar chemotherapy but did not use the mouthwash, to see if the mouthwash helps prevent mouth sores.\n\nParticipants will:\n\nUse a steroid mouthwash (4 times daily) for up to 8 weeks during chemotherapy\n\nComplete a short weekly survey about mouth discomfort during infusion visits",[27],"Oral Mucositis Due to Chemotherapy",[29],"oral mucositis","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":34},"2026-04-02",{"date":38,"type":21},"2028-01",{"name":40,"class":41},"Woman's","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100638415","phase-ii-single-arm-open-label-study-evaluating-the-feasibility-and-safety-of-photobiomodulation-as-an-adjunct-to-standard-supportive-care-for-chemotherapy-induced-oral-mucositis-in-pediatric-patients-with-hematolymphoid-malignancies-100638415","NCT07605234","Phase II Single Arm Open Label Study Evaluating the Feasibility and Safety of Photobiomodulation as an Adjunct to Standard Supportive Care for Chemotherapy Induced Oral Mucositis in Pediatric Patients With Hematolymphoid Malignancies","Phase II Single Arm Study of Photobiomodulation as an Adjunct to Standard Supportive Care for Chemotherapy Induced Oral Mucositis in Pediatric Patients","BEAM","Inclusion Criteria:\n\n* Pediatric patients aged 3 to 14 years\n* Diagnosed with hematolymphoid malignancies\n* Currently receiving chemotherapy\n* Presence of chemotherapy induced oral mucositis of World Health Organization grade 2 or higher at screening\n* Written informed consent obtained from parent or legal guardian along with age appropriate assent from the participant\n\nExclusion Criteria:\n\n* Pre existing oral mucosal disease unrelated to chemotherapy\n* Known photosensitivity or use of photosensitising medications\n* Uncontrolled infection or active bleeding\n* Any medical or clinical condition interfering with protocol compliance","3 Years","14 Years",{"count":54,"type":21},46,[56],"NA","Chemotherapy induced oral mucositis is a common and debilitating complication in pediatric patients receiving chemotherapy for hematolymphoid malignancies. Oral mucositis can cause painful mouth ulcers, difficulty in eating and drinking, impaired nutrition, increased risk of infection, and significant discomfort. In severe cases, oral mucositis may lead to interruptions, delays, or dose modifications in chemotherapy, which can negatively affect cancer treatment outcomes and quality of life. Current management of chemotherapy induced oral mucositis is mainly supportive and includes maintenance of oral hygiene, bland mouth rinses, topical anesthetics, systemic analgesics, antimicrobial therapy when indicated, and nutritional support. However, these measures do not consistently promote healing of the oral mucosa or reduce the duration and severity of oral mucositis.\n\nPhotobiomodulation therapy is a non invasive treatment modality that uses low level red light to stimulate tissue repair, reduce inflammation, and improve pain control. Increasing evidence suggests that photobiomodulation therapy may reduce the severity and duration of chemotherapy induced oral mucositis and improve patient comfort. The treatment is painless, does not involve injections or additional medications, and has shown a favorable safety profile in previous studies. International supportive care guidelines have recommended photobiomodulation therapy in selected oncology settings for the management of oral mucositis.\n\nThe purpose of this Phase II single arm open label interventional study is to evaluate the feasibility and safety of photobiomodulation therapy as an adjunct to standard supportive care in pediatric patients with chemotherapy induced oral mucositis. The study will also explore preliminary clinical outcomes related to oral mucositis severity, pain control, nutritional support, and treatment interruptions.\n\nThis study will be conducted at Tata Memorial Hospital in Mumbai, India. Pediatric patients aged 3 to 14 years with hematolymphoid malignancies who are receiving chemotherapy and develop World Health Organization grade 2 or higher oral mucositis will be eligible for participation. Written informed consent will be obtained from parents or legal guardians along with age appropriate assent from the child before enrollment.\n\nParticipants enrolled in the study will continue to receive standard supportive care for oral mucositis as per institutional protocol. In addition, participants will receive photobiomodulation therapy administered using a handheld low level laser device operating at a wavelength of 660 nanometer. Photobiomodulation therapy will be administered once daily for four consecutive days by trained clinicians. The procedure is expected to take approximately 5 to 10 minutes depending on the extent of oral lesions.\n\nBaseline assessments will include demographic details, diagnosis, chemotherapy information, oral mucositis grading, pain assessment, nutritional status, and routine blood investigation results including absolute neutrophil count where available. Oral mucositis severity will be assessed using World Health Organization oral mucositis grading and National Cancer Institute Common Terminology Criteria for Adverse Events version 6 grading systems. Pain will be assessed using the visual analog scale.\n\nParticipants will undergo daily assessments during the intervention period. Researchers will record oral mucositis severity, pain scores, analgesic requirement, nutritional support requirement, chemotherapy delays or interruptions, and adverse events. Absolute neutrophil count values obtained as part of routine oncologic care will also be documented. No additional blood investigations will be performed specifically for study purposes.\n\nThe primary outcome of the study is feasibility, defined as the proportion of participants who complete the planned photobiomodulation therapy sessions. Secondary outcomes include improvement in oral mucositis severity by Day 7, change in oral mucositis grade over predefined time points, time to resolution of oral mucositis, change in pain scores, analgesic consumption, nutritional support requirement, chemotherapy delays or interruptions, trends in absolute neutrophil count, and safety and tolerability of photobiomodulation therapy.\n\nParticipants will be followed until Day 10 after initiation of therapy for final clinical assessment and documentation of any late adverse events. The study aims to generate preliminary data regarding the feasibility and safety of photobiomodulation therapy in pediatric oncology patients with chemotherapy induced oral mucositis. If found to be feasible and well tolerated, photobiomodulation therapy may become a practical and cost effective adjunctive supportive care option for children receiving chemotherapy.",[27,59],"Hematolymphoid Malignancies",[61,62,63,64,65,59,66,67],"Photobiomodulation","Low Level Laser Therapy","Oral Mucositis","Chemotherapy","Pediatric Oncology","Supportive Care","mouth ulcers","NOT_YET_RECRUITING","2026-05-18",{"date":71,"type":34},"2026-05-22",{"date":73,"type":21},"2026-06-01",{"date":75,"type":21},"2027-04-23",{"name":77,"class":78},"Tata Memorial Hospital","OTHER_GOV",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":18,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":42},"100598561","phase-2-propolis-for-management-of-chemotherapy-induced-oral-mucositis-in-pediatric-patients-100598561","NCT07073092","Propolis for Management of Chemotherapy-Induced Oral Mucositis in Pediatric Patients","Propolis for Management of Chemotherapy-Induced Oral Mucositis in Pediatric Patients: A Randomized Controlled Clinical Trial With Biochemical Analysis","Inclusion Criteria:\n\n* Children of both genders less than 18 years receiving intensive chemotherapy.\n* Oncology patients receiving intensified chemotherapy at Oncology unit, Children's Hospital, Ain Shams University, Egypt, who meet the following criteria:\n\n  * Taking intensified chemotherapy\n  * A healthy oral mucosa.\n\nExclusion Criteria:\n\n* Allergy to bee products.\n* Severe systemic illness unrelated to cancer (Diabetes, Hypertension, …)\n* Inability to take oral medication or unwillingness to participate in the study\n* Radiotherapy in the head and neck area.\n* Malignant or potentially malignant lesions of the oral cavity.\n* Undergoing any other procedures to prevent oral mucositis except standard oral care.\n* Patients are unable to commit to the study.",true,"2 Years",{"count":89,"type":21},50,[91],"PHASE2","The goal of this clinical trial is to evaluate the efficacy of propolis in the prevention of oral mucositis and reducing pain score in children undergoing chemotherapy, and assessing its impact on body mass index, pediatric quality of life and total antioxidant assay. The main question it aims to answer is:\n\nWhat is the effect of propolis on oral mucositis scores in children undergoing chemotherapy?\n\nParticipants will:\n\nTake propolis 3 times daily for 21 days follow up weekly for 3 weeks",[27],"2025-07-17",{"date":96,"type":34},"2025-07-18",{"date":98,"type":21},"2025-07-15",{"date":100,"type":21},"2026-01-30",{"name":102,"class":41},"Ain Shams University"]